Secretion of sHLA-G molecules in malignancies

Seminars in Cancer Biology

Volumn 13, Issue 5, 2003, Pages 371-377

  Rebmann, Vera ^a   Regel, Jens ^a   Stolke, Dietmar ^a   Grosse Wilde, Hans ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

ELISpot; Malignant disease; Monocytes; sHLA G

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; HLA G ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4;

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GLIOMA; HUMAN; IMMUNOSURVEILLANCE; INTRON; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOCYTE; NATURAL KILLER CELL; OVARY CANCER; PROTEIN SECRETION; T LYMPHOCYTE; TH1 CELL; TUMOR CELL;

EID: 0742322611     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00028-2     Document Type: Article

References (34)

1. Le Bouteiller P., Solier C., Proll J., Aguerre-Girr M., Fournel S., Lenfant F. Placental HLA-G protein expression in vivo: where and what for? Hum. Reprod. 5:1999;223-233.
2. van der Ven K., Skrablin S., Ober C., Krebs D. HLA-G polymorphisms: ethnic differences and implications for potential molecule function. Am. J. Reprod. Immunol. 40:1998;145-157.
3. McMaster M.T., Librach C.L., Zhou Y., Lim K.H., Janatpour M.J., DeMars R.et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J. Immunol. 154:1995;3771-3778.
4. Mallet V., Blaschitz A., Crisa L., Schmitt C., Fournel S., King A.et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int. Immunol. 111:1999;889-898.
5. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A.et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. U.S.A. 95:1998;4510-4515.
6. Wagner S.N., Rebmann V., Willers C.P., Grosse-Wilde H., Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet. 356:2000;220-221.
7. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R.et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168:2002;4772-4780.
8. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D.et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 61:2001;6838-6845.
9. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G.et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159:2001;817-824.
10. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 99:2002;609-617.
11. Frumento G., Franchello S., Palmisano G.L., Nicotra M.R., Giacomini P., Loke Y.W.et al. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gamma-IFN treatment. Tissue Antigens. 56:2000;30-37.
12. Palmisano G.L., Pistillo M.P., Fardin P., Capanni P., Nicolo G., Salvi S.et al. Analysis of HLA-G expression in breast cancer tissues. Hum. Immunol. 63:2002;969-976.
13. Lefebvre S., Antoine M., Uzan S., McMaster M., Dausset J., Carosella E.D.et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196:2002;266-274.
14. Riteau B., Rouas-Freiss N., Menier C., Paul P., Dausset J., Carosella E.D. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoprotein inhibit NK and antigen-specific CTL cytolysis. J. Immunol. 166:2001;5018-5026.
15. Rouas-Freiss N., Marchal R.E., Kirszenbaum M., Dausset J., Carosella E.D. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc. Natl. Acad. Sci. U.S.A. 94:1997;249-254.
16. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, et al. Functional role of HLA-G up-regulation in renal cell carcinoma. Cancer Res 2003 (in press).
17. Paul P., Cabestre F.A., Ibrahim E.C., Lefebvre S., Khalil-Daher I., Vazeux G.et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum. Immunol. 61:2000;1138-1149.
18. Lee N., Malacko A.R., Ishitani A., Chen M.C., Bajorath J., Marquardt H. et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity. 3:1995;591-600.
19. Moreau P., Rousseau P., Rouas-Freiss N., Le Discorde M., Dausset J., Carosella E.D. HLA-G protein processing and transport to the cell surface. Cell Mol. Life Sci. 59:2002;1460-1466.
20. + cells by interacting with CD8. J. Immunol. 164:2000;6100-6104.
21. Solier C., Aguerre-Girr M., Lenfant F., Campan A., Berrebi A., Rebmann V.et al. Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur. J. Immunol. 32:2002;3576-3586.
22. + T cell regulatory mechanism. Proc. Natl. Acad. Sci. U.S.A. 98(21):2001;12150-12155.
23. Kapasi K., Albert S.E., Yie S., Zavazava N., Librach C.L. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology. 101:2000;191-200.
24. Rebmann V., Pfeiffer K., Päßler M., Ferrone S., Maier S., Weiss E.et al. Detection of soluble HLA-G in plasma and amniotic fluids. Tissue Antigens. 53:1999;14-22.
25. Desai S., Wang X., Noronha E.J., Zhou Q., Rebmann V., Grosse-Wilde H.et al. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on β2-microglobulin-associated and β2 microglobulin-free HLA class I heavy chains. J. Immunol. 165:2000;3275-3283.
26. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., Reinhold U. sHLA-G serum level is elevated in melanoma patients and is further increased by IFN-alpha immunotherapy. Cancer. 92:2001;369-376.
27. Singer G, Rebmann V, Chen YC, Cheng CC, Liu HT, Ali SZ, et al. HLA-G is a potential tumor marker in malignant effusion. Clin Cancer Res 2003 (submitted).
28. Park B., Lee S., Kim E., Chang S., Jin M., Ahn K. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity. 15:2001;213-224.
29. Fujii T., Ishitani A., Geraghty D.E. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J. Immunol. 153:1994;5516-5524.
30. Neefjes J.J., Doxiadis I., Stam N.J., Beckers C.J., Ploegh H.L. An analysis of class I antigens of man and other species by one-dimensional IEF and immunoblotting. Immunogenetics. 23:1986;164-171.
31. Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., Gourand L. et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J. Biol. Chem. 276:2001;6133-6139.
32. Lefebvre S., Moreau P., Guiard V., Ibrahim E.C., Adrian-Cabestre F., Menier C.et al. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J. Reprod. Immunol. 43:1999;213-224.
33. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J.et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11:1999;803-811.
34. Bamberger A.M., Jenatschke S., Schulte H.M., Bamberger M.C. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J. Clin. Endocrinol. Metab. 85:2000;3932-3936.